Replies to post #10267 on Momenta Pharmaceuticals, Inc. (MNTA)

[joethdo]

Thanks. That's helpful.

Given that timeline, the Obama administration's goal of reducing health care costs, and the May, 2014 patent expiration, the chances of seeing approval this year are decent. (20 to 30 percent? A WAG of course.)

All this assumes, of course, that MNTA was able to replicate Copaxone, which I believe they have.